ResearchObstetricsFolic acid supplementation in early second trimester and the risk of preeclampsia
Section snippets
Materials and Methods
The Ottawa and Kingston (OaK) Birth Cohort recruited nontransferred, consenting women between 12-20 weeks’ gestation during their prenatal visit at the Ottawa Hospital and Kingston General Hospital. The current analysis included subjects from phase I of the OaK Birth Cohort, which started in October 2002 and ended in December 2005. The research nurses explained to pregnant women the purpose of the study, what would be expected from them, and what they could expect from the study. For
Results
A total of 4024 women were approached to participate in the study; 3134 (78%) agreed and were recruited. Among them, 70 women were excluded because of twin births and 113 women were excluded because of missing information such as gestational age at delivery, birthweight, or sex (59) and lost to follow-up because of the participant’s relocation outside the study center (54), leaving 2951 subjects for final analysis.
Ninety-two percent of the study subjects were taking folic acid supplementation
Comment
Our prospective cohort study in a cohort of Canadian women found that 92% had supplementation with folic acid or multivitamins containing folic acid in the early second trimester, and among them, most (>95%) had a supplementation of 1.0 mg or higher, twice the recommended level for the prevention of neural tube defects by Health Canada.12
Supplementation of multivitamins containing folic acid was associated with increased serum folate, lowered plasma homocysteine, and reduced risk of
Acknowledgments
We acknowledge the following people because without their commitment and expertise, this project would not have been possible: the OMNI Research Nurse Group (Ottawa and Lucy Chura, RN, BScN, study coordinator, Queen’s Perinatal Research Unit research team (Queen’s Perinatal Research Unit Kingston and Lizy Kodiattu, MD); Dr. George Tawagi and team (Ottawa Hospital–Civic Campus); and Carol Ann Jodouin, Department of Laboratory Medicine, Ottawa Hospital.
References (25)
- et al.
Antioxidant therapy to prevent preeclampsia
Semin Nephrol
(2004) - et al.
Folic acid and homocysteine metabolic defects and the risk of placenta abruption, pre-eclampsia and spontaneous pregnancy loss: a systematic review
Placenta
(1999) - et al.
Genetic determinants of heritable venous thrombosis: genotyping methods for factor V(Leiden)A1691G, methylenetetrahydrofolate reductase C677T, prothrombin G20210A mutation, and algorithms for venous thrombosis investigations
Clin Biochem
(1999) - et al.
Maternal-perinatal morbidity and mortality associated with adolescent pregnancy in Latin America: cross-section study
Am J Obstet Gynecol
(2005) - et al.
The 677 C-T methylenetetrahydrofolate reductase mutation does not predict increased maternal homocysteine during pregnancy
Obstet Gynecol
(2003) - et al.
Changes in homocysteine levels during normal pregnancy
Am J Obstet Gynecol
(1999) - et al.
Second-trimester plasma homocysteine levels and pregnancy-induced hypertension, preeclampsia, and intrauterine growth restriction
Am J Obstet Gynecol
(2000) - et al.
Plasma homocysteine concentration is increased in preeclampsia and is associated with evidence of endothelial activation
Am J Obstet Gynecol
(1998) - et al.
Serum homocysteine at 16 weeks and subsequent preeclampsia
Obstet Gynecol
(2001) - et al.
Vitamins in pre-eclampsia (VIP) Trial ConsortiumVitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomized placebo-controlled trial
Lancet
(2006)
ACOG practice bulletinDiagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. American College of Obstetricians and Gynecologists
Int J Gynaecol Obstet
Hypertensive diseases of pregnancy and risk of hypertension and stroke in later life: results from cohort study
BMJ
Cited by (0)
Cite this article as: Wen SW, Chen X-K, Rodger M, et al. Folic acid supplementation in early second trimester and the risk of preeclampsia. Am J Obstet Gynecol 2008;198:45.e1-45.e7.
Supported in part by a grant from the Canadian Institute for Health Research (Grant MOP 53188). S.W.W., G.N.S., R.J.S., and M.C.W. are recipients of a New Investigators’ Award from the Canadian Institute for Health Research. M.R. is a Clinical Investigator of the Heart and Stroke Foundation of Canada, and X.-K.C. and Q.Y. are Canadian Institute for Health Research/Strategic Training Initiatives of Research in Reproductive Health Sciences postdoctor fellows.